1 Duquesne University Mylan School of Pharmacy, Pittsburgh, Pennsylvania.
2 University of Georgia College of Pharmacy, Athens, Georgia.
J Manag Care Spec Pharm. 2017 Feb;23(2):136-162. doi: 10.18553/jmcp.2017.23.2.136.
Cancer is a leading cause of death with substantial financial costs. While significant data exist on the economic burden of care, less is known about the indirect costs of treatment and, specifically, the effect on work productivity of patients and their caregivers. To examine the full effect of cancer and the potential value of new therapies, all aspects of care, including indirect costs and patient-reported outcomes, should be evaluated.
To perform a systematic review of the literature examining the effect of cancer treatment on work productivity in patients and their caregivers.
Articles, abstracts, and bibliographies were searched in MEDLINE, Cochrane, Scopus, CINAHL, and conference lists from the American Society of Clinical Oncology, International Society for Pharmacoeconomics and Outcomes Research, and Academy of Managed Care Pharmacy up to January 2016. The PRISMA guidelines were used. Controlled search terminology included individual pharmacologic therapies for cancer and terms related to patient and caregiver work productivity. Citations were included if they evaluated the effect of cancer treatment on work productivity, used and described productivity assessments and instruments, and were written in English. Studies that reported only clinical outcomes or assessed only nonpharmacological treatments were excluded. Identified studies were screened and extracted for study inclusion by 2 independent reviewers, with adjudication by 2 secondary reviewers during the final eligibility phase.
Of 978 potential citations, 62 articles or abstracts were included. Forty-six studies (74.2%) evaluated patient-related productivity; 10 studies (16.1%) focused on caregivers, and 6 studies (9.7%) were a combination. Sixteen countries contributed literature, including 26 studies (41.2%) conducted in the United States. The most commonly studied cancer was breast cancer (53.2%). Nearly 22% of the studies were conducted on multiple types of cancer. The significant diversity of study methodologies and measurements rendered a single unifying conclusion difficult. A variety of metrics were used to quantify productivity (hours lost, return to work, change of status, and activity impairment). The Work Productivity and Activity Impairment questionnaire was the most commonly used standardized tool (n = 9; 14.5%). Factors found to be associated with impairment in productivity included disease- and treatment-related effects, such as disease progression and severity, cognitive and neurological impairments, poor physical and psychological status, receipt of chemotherapy, and time and expenses required to receive therapy.
This review highlights the considerable variety of studies that have assessed work productivity for cancer treatment and the multifaceted reasons affecting patients and caregivers. With increasing emphasis being given to understanding the value that patients assign to various aspects of cancer treatment, more streamlined information on productivity may be important to patients as they play a greater role in selecting treatment goals through shared decision making with their providers.
This study was funded by Novartis Pharmaceuticals, which provided the concept, general oversight, and research collaboration on the project. Covvey and Kamal received research funding from Novartis Pharmaceuticals and the College of Psychiatric and Neurologic Pharmacists. Zacker is employed by, and owns stock in, Novartis Pharmaceuticals. A related poster abstract was presented at the Academy of Managed Care Pharmacy April 2016 Annual Meeting and published as Kamal KM, Covvey JR, Dashputre A, Ghosh S, Zacker C. A conceptual framework for valuebased oncology treatment: a societal perspective. J Manag Care Spec Pharm. 2016;22(4 Suppl A):S28. A publication-only abstract was presented at the American Society of Clinical Oncology 2016 Annual Meeting and published as Covvey JR, Kamal KM, Dashputre A, Ghosh S, Zacker C. The impact of cancer treatment on work productivity of patients and caregivers: a systematic review of the evidence. J Clin Oncol. 2016;34(Suppl):e18249. Study concept and design were contributed by Zacker, Kamal, and Covvey. Dashputre and Ghosh took the lead in data collection, along with Kamal and Covvey, and data interpretation was performed primarily by Shah and Bhosle, along with Ghosh, Dashputre, Covvey, and Kamal. The manuscript was written by Kamal, Covvey, Shah, and Bhosle and revised primarily by Zacker, along with Shah, Bhosle, Kamal, and Covvey.
癌症是导致死亡的主要原因,其医疗费用也相当可观。尽管有大量关于护理经济负担的数据,但对于治疗的间接成本,尤其是对患者及其照顾者工作生产力的影响,了解甚少。为了全面评估癌症的影响以及新疗法的潜在价值,应评估护理的所有方面,包括间接成本和患者报告的结果。
系统评价文献,以了解癌症治疗对患者及其照顾者工作生产力的影响。
在 MEDLINE、Cochrane、Scopus、CINAHL 和美国临床肿瘤学会、国际药物经济学与结果研究学会和管理医疗保健药房协会的会议列表中搜索文章、摘要和参考文献,检索时间截至 2016 年 1 月。使用 PRISMA 指南。受控搜索术语包括癌症的个体药物治疗以及与患者和照顾者工作生产力相关的术语。如果研究评估了癌症治疗对工作生产力的影响、使用和描述了生产力评估和工具,并且以英文书写,则将其纳入研究。仅报告临床结果或仅评估非药物治疗的研究被排除在外。由 2 名独立评审员筛选和提取研究,在最终合格阶段由 2 名次要评审员进行裁决。
在 978 个潜在引用中,有 62 篇文章或摘要被纳入。46 项研究(74.2%)评估了患者相关的生产力;10 项研究(16.1%)关注照顾者,6 项研究(9.7%)为两者结合。16 个国家提供了文献,其中包括 26 项在美国进行的研究(41.2%)。最常研究的癌症是乳腺癌(53.2%)。近 22%的研究针对多种类型的癌症。研究方法和测量的显著多样性使得难以得出单一的统一结论。各种指标被用于量化生产力(损失的工时、重返工作岗位、状态变化和活动障碍)。工作生产力和活动障碍问卷是使用最广泛的标准化工具(n=9;14.5%)。与生产力受损相关的因素包括疾病和治疗相关的影响,如疾病进展和严重程度、认知和神经功能障碍、身体和心理状况不佳、接受化疗以及接受治疗所需的时间和费用。
本综述强调了评估癌症治疗对工作生产力影响的大量研究,以及影响患者和照顾者的多方面原因。随着人们越来越重视了解患者对癌症治疗各个方面的价值,为患者提供更精简的生产力信息可能很重要,因为他们通过与提供者共同制定治疗目标,在选择治疗目标方面发挥着更大的作用。
这项研究由诺华制药公司资助,该公司提供了项目的概念、总体监督和研究合作。Covvey 和 Kamal 从诺华制药公司获得了研究资金和药学院的认可。Zacker 受雇于诺华制药公司并拥有其股票。一个相关的海报摘要在 2016 年药学院管理保健药房协会年会上提交并发表,题为 Kamal KM、Covvey JR、Dashputre A、Ghosh S、Zacker C。一个仅发表摘要的海报在 2016 年美国临床肿瘤学会年会上提交并发表,题为 Covvey JR、Kamal KM、Dashputre A、Ghosh S、Zacker C。研究概念和设计由 Zacker、Kamal 和 Covvey 提出。Dashputre 和 Ghosh 与 Kamal 和 Covvey 一起主要负责数据收集,数据解释主要由 Shah 和 Bhosle 进行,同时 Ghosh、Dashputre、Covvey 和 Kamal 也参与其中。手稿由 Kamal、Covvey、Shah 和 Bhosle 撰写,主要由 Zacker 修订,同时由 Shah、Bhosle、Kamal 和 Covvey 修订。